Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery

Wen Hwa Lee

doi:10.1371/journal.pbio.1002164

Loading metrics

Open Access

The Community Page is a forum for organizations and societies to highlight their efforts to enhance the dissemination and value of scientific knowledge.

See all article types »

Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery

Wen Hwa Lee

* E-mail: wenhwa.lee@sgc.ox.ac.uk

Affiliation Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
⨯

Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery

Wen Hwa Lee

Published: June 4, 2015
https://doi.org/10.1371/journal.pbio.1002164

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Drug discovery
Is the Subject Area "Drug discovery" applicable to this article?

Thanks for your feedback.
Phase I clinical investigation
Is the Subject Area "Phase I clinical investigation" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Leukemia
Is the Subject Area "Leukemia" applicable to this article?

Thanks for your feedback.
Prostate cancer
Is the Subject Area "Prostate cancer" applicable to this article?

Thanks for your feedback.
Drug research and development
Is the Subject Area "Drug research and development" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.